Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Core Points - Basilea Pharmaceutica Ltd reported that shareholders approved all proposals of the board of directors at the annual general meeting for the financial year 2024 [1][2] Group 1: Shareholder Approvals - Shareholders approved the annual report, financial statements, and consolidated financial statements for the financial year 2024 [2] - The accumulated deficit will be carried forward, and the discharge of the board of directors and management committee members was approved [2] Group 2: Board Elections and Compensation - Mr. Stephan Schindler was elected as chairman, and several members were re-elected to the board of directors, with terms lasting until the AGM 2026 [3] - Shareholders approved the maximum aggregate amount of compensation for the board of directors and management committee for the upcoming financial year [4] Group 3: Auditor Appointment and Proxy - Dr. Caroline Cron was re-elected as independent proxy until the next AGM, and Ernst & Young Ltd was appointed as auditors for the financial year 2025 [5] Group 4: Company Overview - Basilea is a commercial-stage biopharmaceutical company focused on developing innovative drugs for severe bacterial and fungal infections, with two hospital brands launched: Cresemba and Zevtera [7]